Designed Polymer Micelle for Clearing Amyloid Protein Aggregates via Up-Regulated Autophagy
Source abstract
Abstract
Inhibiting protein aggregation under intra-/extracellular space and clearing protein aggregates from the brain are two critical issues for the treatment of various neurodegenerative diseases. Although a variety of anti-amyloidogenic chemicals/biochemicals have been identified for inhibiting such protein aggregation, clearing protein aggregates is a challenging issue. Here we report a designed biopolymer micelle of 15-30 nm hydrodynamic size that can clear protein aggregates from cells via an up-regulated autophagy process. The polymer has a polyaspartic acid backbone and is functionalized with fatty amine, arginine, and primary amine for inducing self-assembly, enhancing cell uptake, and up-regulating autophagy processes, respectively. The polymer micelle (PM) enters into the cell via lipid raft endocytosis, is transported to the perinuclear region where the protein oligomer/aggregate predominantly localizes, clears aggregated protein from the cell, and enhances the cell's survival against toxic protein aggregates. The designed PM may be used as a drug delivery carrier for anti-amyloidogenic drugs for enhanced efficacy in the treatment of neurodegenerative diseases.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Alzheimer's disease research and treatments · Autophagy in Disease and Therapy · Pickering emulsions and particle stabilization
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Centre for Advanced Materials and School of Materials Science, Indian Association for the Cultivation of Science, 2A & 2B Raja S. C. Mullick Road, Kolkata 700032, India
Cellular and Molecular Neuroscience Laboratory, National Brain Research Centre, Manesar, NH-8, Gurgaon 122051, India
Funding
Council of Scientific and Industrial Research · Nano Mission Council, Department of Science and Technology
References (36)
Show source-provided references
1. 10.1038/nature0226410.1038/nature02264 ↗
2. 10.1038/nm106610.1038/nm1066 ↗
3. 10.1146/annurev.pathol.1.110304.10011310.1146/annurev.pathol.1.110304.100113 ↗
4. 10.1038/nrneurol.2014.2410.1038/nrneurol.2014.24 ↗
5. 10.1039/C6CS00731G10.1039/C6CS00731G ↗
6. 10.1021/ar500152x10.1021/ar500152x ↗
7. 10.1021/acs.biomac.8b0067110.1021/acs.biomac.8b00671 ↗
8. 10.1186/alzrt26910.1186/alzrt269 ↗
9. 10.1136/bmj.h406410.1136/bmj.h4064 ↗
10. 10.1038/nm.323210.1038/nm.3232 ↗
11. 10.1111/bpa.1254510.1111/bpa.12545 ↗
12. 10.4161/auto.1949610.4161/auto.19496 ↗
13. 10.1523/JNEUROSCI.1356-10.201010.1523/JNEUROSCI.1356-10.2010 ↗
14. 10.1073/pnas.070802210510.1073/pnas.0708022105 ↗
15. 10.1016/j.nbd.2010.05.01410.1016/j.nbd.2010.05.014 ↗
16. 10.1016/j.ejphar.2006.06.02510.1016/j.ejphar.2006.06.025 ↗
17. 10.1016/j.neurobiolaging.2010.05.02110.1016/j.neurobiolaging.2010.05.021 ↗
18. 10.1038/mp.2012.11510.1038/mp.2012.115 ↗
19. 10.1021/cr400372p10.1021/cr400372p ↗
20. 10.1016/j.copbio.2015.08.01610.1016/j.copbio.2015.08.016 ↗
21. 10.1016/j.biomaterials.2010.04.01410.1016/j.biomaterials.2010.04.014 ↗
22. 10.1021/nn202155y10.1021/nn202155y ↗
23. 10.1021/nn505073u10.1021/nn505073u ↗
24. 10.1021/nn500376w10.1021/nn500376w ↗
25. 10.1038/srep1436110.1038/srep14361 ↗
26. 10.1016/j.biomaterials.2015.08.04410.1016/j.biomaterials.2015.08.044 ↗
27. 10.1038/srep3441310.1038/srep34413 ↗
28. 10.1002/smll.20150370910.1002/smll.201503709 ↗
29. 10.1021/acs.molpharmaceut.6b0040510.1021/acs.molpharmaceut.6b00405 ↗
30. 10.1038/s41467-018-04255-z10.1038/s41467-018-04255-z ↗
31. 10.1021/acsami.7b0651010.1021/acsami.7b06510 ↗
32. 10.1021/acs.langmuir.6b0028210.1021/acs.langmuir.6b00282 ↗
33. 10.1021/acsami.6b0685310.1021/acsami.6b06853 ↗
34. 10.1021/acs.jpclett.5b0173910.1021/acs.jpclett.5b01739 ↗
35. 10.1111/j.1742-4658.2010.07568.x10.1111/j.1742-4658.2010.07568.x ↗
36. 10.2337/db06-157910.2337/db06-1579 ↗